The Mirena coil is a contraceptive method that reduces the duration and intensity of periods and can be used for an extended period.

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

The recommended initial treatments for endometriosis are NSAIDs and/or paracetamol. Ibuprofen is the most suitable option for managing pain, and it should be tried first. If the pain is not relieved with one medication, a combination of paracetamol and NSAIDs can be used. If these options are not effective, hormonal treatment can be considered. Codeine is not the first-line treatment and should only be used after other options have been tried. The combined oral contraceptive pill and Mirena coil are also not the initial interventions and should only be considered if analgesia and hormonal treatments are unsuccessful.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Pre-eclampsia can be diagnosed based on the presence of high levels of protein in the urine and hypertension. To prevent the development of eclampsia, magnesium sulphate is administered, while labetalol is used to manage high blood pressure. If a cardiotocography (CTG) shows late decelerations and foetal bradycardia, this is a concerning sign and may necessitate an emergency caesarean section. Induction would not be recommended if the CTG is abnormal.

Cardiotocography (CTG) is a medical procedure that measures pressure changes in the uterus using either internal or external pressure transducers. It is used to monitor the fetal heart rate, which normally ranges between 100-160 beats per minute. There are several features that can be observed during a CTG, including baseline bradycardia (heart rate below 100 beats per minute), which can be caused by increased fetal vagal tone or maternal beta-blocker use. Baseline tachycardia (heart rate above 160 beats per minute) can be caused by maternal pyrexia, chorioamnionitis, hypoxia, or prematurity. Loss of baseline variability (less than 5 beats per minute) can be caused by prematurity or hypoxia. Early deceleration, which is a decrease in heart rate that starts with the onset of a contraction and returns to normal after the contraction, is usually harmless and indicates head compression. Late deceleration, on the other hand, is a decrease in heart rate that lags behind the onset of a contraction and does not return to normal until after 30 seconds following the end of the contraction. This can indicate fetal distress, such as asphyxia or placental insufficiency. Variable decelerations, which are independent of contractions, may indicate cord compression.

The Benefits and Risks of Oral Contraceptives in Relation to Cancer

Oral contraceptives have been a topic of controversy when it comes to their association with cancer in women. However, various studies have shown that they can have both positive and negative effects on different types of cancer.

Breast Cancer:
The Collaborative Group on Hormonal Factors in Breast Cancer conducted a comprehensive analysis and found that current oral contraceptive users and those who had used them within the past 1-4 years had a slightly increased risk of breast cancer. However, the risk is small and resulting tumors spread less aggressively than usual.

Dysmenorrhoea:
For women with primary dysmenorrhoea who do not wish to conceive, a 3-6 month trial of hormonal contraception is reasonable. Monophasic combined oral contraceptives containing 30-35 μg of ethinylestradiol and norethisterone, norgestimate or levonorgestrel are usually the first choice.

Ovarian Cancer:
Oral contraceptives have been noted to prevent epithelial ovarian carcinoma, with studies showing an approximately 40% reduced risk of malignant and borderline ovarian epithelial cancer. This protection lasts for at least 15 years after discontinuation of use and increases with duration of use.

Endometrial Cancer:
Use of oral contraceptives is associated with a 50% reduction of risk of endometrial adenocarcinoma. Protection appears to persist for at least 15 years following discontinuation of use.

Colorectal Cancer:
Women who take combined oral contraceptives are 19% less likely to develop colorectal cancer.

In conclusion, while there are some risks associated with oral contraceptives, they also have benefits in reducing the risk of certain types of cancer. It is important for women to discuss their individual risks and benefits with their healthcare provider when considering the use of oral contraceptives.

Postpartum haemorrhage caused by uterine atony can be treated with various medical options such as oxytocin, ergometrine, carboprost and misoprostol.

Uterine atony is the primary cause of postpartum haemorrhage, which occurs when the uterus fails to contract fully after the delivery of the placenta, leading to difficulty in achieving haemostasis. This condition is often associated with overdistension, which can be caused by multiple gestation, macrosomia, polyhydramnios or other factors.

In addition to the standard approach for managing PPH, including an ABC approach for unstable patients, the following steps should be taken in sequence:

1. Bimanual uterine compression to stimulate contraction manually
2. Intravenous oxytocin and/or ergometrine
3. Intramuscular carboprost
4. Intramyometrial carboprost
5. Rectal misoprostol
6. Surgical intervention such as balloon tamponade

(RCOG Green-top Guideline No. 52)

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

Women who have had a previous baby affected by early- or late-onset GBS disease should be offered maternal intravenous antibiotic prophylaxis. The recommended option is to prescribe intrapartum intravenous benzylpenicillin or ampicillin to the mother. This is according to the Royal College of Obstetricians and Gynaecologists guidelines published in 2017. Administering intravenous benzylpenicillin to the child at birth is not appropriate unless they show signs of neonatal sepsis. Prescribing intrapartum intravenous ceftazidime is also not recommended. Monitoring the newborn for signs of sepsis for the next 72 hours is not sufficient in this case. The best approach is to administer antibiotics to the mother to prevent the development of neonatal sepsis.

Group B Streptococcus (GBS) is a common cause of severe infection in newborns. It is estimated that 20-40% of mothers carry GBS in their bowel flora, which can be passed on to their infants during labor and lead to serious infections. Prematurity, prolonged rupture of membranes, previous sibling GBS infection, and maternal pyrexia are all risk factors for GBS infection. The Royal College of Obstetricians and Gynaecologists (RCOG) has published guidelines on GBS management, which include not offering universal screening for GBS to all women and not offering screening based on maternal request. Women who have had GBS detected in a previous pregnancy should be offered intrapartum antibiotic prophylaxis (IAP) or testing in late pregnancy and antibiotics if still positive. IAP should also be offered to women with a previous baby with GBS disease, women in preterm labor, and women with a fever during labor. Benzylpenicillin is the preferred antibiotic for GBS prophylaxis.

Taking metronidazole and alcohol together can result in a disulfiram-like reaction, so patients should be cautioned against consuming alcohol while on the medication. Metronidazole is not associated with cholestasis, hepatotoxicity, or QT prolongation. As an enzyme inhibitor, metronidazole enhances the efficacy of the COCP. While Stevens-Johnson syndrome is a rare side effect of metronidazole, a photosensitive rash is not typically observed.

Metronidazole is an antibiotic that functions by producing reactive cytotoxic metabolites within bacteria. This medication can cause adverse effects such as a disulfiram-like reaction when combined with alcohol and an increased anticoagulant effect when taken with warfarin.

Cervical cancer screening now includes testing all samples for hrHPV. If the result is positive, cytology is performed. If the cytology is normal, the test is repeated after 12 months.

Upon repeat testing, if the result is now negative for hrHPV, the patient can resume normal recall. However, if the result is still positive for hrHPV and the cytology is normal, another repeat test should be done after 12 months. This applies to the patient in the given scenario.

If the second repeat test at 24 months is negative for hrHPV, the patient can return to normal recall. However, if the result is positive for hrHPV, they should be referred for colposcopy.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Pregnant women who have mild or moderate gestational hypertension, are beyond 37 weeks of pregnancy, and exhibit pre-eclampsia symptoms, should be advised to deliver their baby within 24 to 48 hours as per the existing recommendations.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

The symptoms of HELLP syndrome, a severe form of pre-eclampsia, include haemolysis (H), elevated liver enzymes (EL), and low platelets (LP). A patient with this condition may experience malaise, nausea, vomiting, and headache, as well as hypertension with proteinuria and epigastric and/or upper abdominal pain. The patient in this case meets the requirements for a diagnosis of HELLP syndrome.

Liver Complications During Pregnancy

During pregnancy, there are several liver complications that may arise. One of the most common is intrahepatic cholestasis of pregnancy, which occurs in about 1% of pregnancies and is typically seen in the third trimester. Symptoms include intense itching, especially in the palms and soles, as well as elevated bilirubin levels. Treatment involves the use of ursodeoxycholic acid for relief and weekly liver function tests. Women with this condition are usually induced at 37 weeks to prevent stillbirth, although maternal morbidity is not typically increased.

Another rare complication is acute fatty liver of pregnancy, which may occur in the third trimester or immediately after delivery. Symptoms include abdominal pain, nausea and vomiting, headache, jaundice, and hypoglycemia. Severe cases may result in pre-eclampsia. ALT levels are typically elevated, and support care is the primary management until delivery can be performed once the patient is stabilized.

Finally, conditions such as Gilbert’s and Dubin-Johnson syndrome may be exacerbated during pregnancy. Additionally, HELLP syndrome, which stands for haemolysis, elevated liver enzymes, and low platelets, is a serious complication that can occur in the third trimester and requires immediate medical attention. Overall, it is important for pregnant women to be aware of these potential liver complications and to seek medical attention if any symptoms arise.

Anticoagulant Therapy for Deep Vein Thrombosis in Pregnancy

Deep vein thrombosis (DVT) is a serious condition that can occur during pregnancy. Any woman with symptoms or signs suggestive of DVT should undergo objective testing and receive treatment with low-molecular-weight heparin (LMWH) immediately until the diagnosis is excluded. LMWH should be given in doses titrated against the woman’s weight and can be administered once daily or in two divided doses. It does not cross the placenta and has a lower risk of bleeding and heparin-induced osteoporosis compared to unfractionated heparin (UH). Fondaparinux, argatroban, or r-hirudin may be considered for pregnant women who cannot tolerate heparin.

Aspirin is not recommended for thromboprophylaxis in obstetric patients, except for pregnant women with a known history of antiphospholipid syndrome. Intravenous UH is the preferred initial treatment for massive pulmonary embolism with cardiovascular compromise during pregnancy and the puerperium. Warfarin should not be used for antenatal DVT treatment due to its adverse effects on the fetus. Postnatal therapy can be with LMWH or oral anticoagulants, but regular blood tests are needed to monitor warfarin.

Compression duplex ultrasonography should be performed when there is clinical suspicion of DVT. D-dimer testing should not be used in the investigation of acute DVT in pregnancy. Before anticoagulant therapy is started, blood tests should be taken for a full blood count, coagulation screen, urea and electrolytes, and liver function tests. Thrombophilia screening before therapy is not recommended.

Pregnant women with symptomatic bacterial vaginosis (BV) should be offered treatment using oral metronidazole. If BV is incidentally detected in a pregnant woman without symptoms, it is advisable to discuss with her obstetrician whether treatment is necessary. High-dose regimens are not recommended during pregnancy. In case the woman prefers a topical treatment or is unable to tolerate oral metronidazole, intravaginal metronidazole gel or clindamycin cream can be used as alternative choices. However, oral clindamycin is not widely recommended in primary care due to the increased risk of pseudomembranous colitis. This information is sourced from NICE CKS – Bacterial Vaginosis.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

GBS bacteriuria is linked to an increased risk of chorioamnionitis and neonatal sepsis, therefore, the Royal College of Obstetricians and Gynaecologists recommends that women with GBS bacteriuria should receive intrapartum antibiotics along with appropriate treatment upon diagnosis. In cases where the patient is not allergic to penicillin, intravenous benzylpenicillin should be administered as soon as possible after the onset of labor and then every 4 hours until delivery. Postnatal antibiotic treatment is not necessary unless there are indications of neonatal infection. Caesarean section is not recommended. [RCOG Green-top Guideline No. 36]

Group B Streptococcus (GBS) is a common cause of severe infection in newborns. It is estimated that 20-40% of mothers carry GBS in their bowel flora, which can be passed on to their infants during labor and lead to serious infections. Prematurity, prolonged rupture of membranes, previous sibling GBS infection, and maternal pyrexia are all risk factors for GBS infection. The Royal College of Obstetricians and Gynaecologists (RCOG) has published guidelines on GBS management, which include not offering universal screening for GBS to all women and not offering screening based on maternal request. Women who have had GBS detected in a previous pregnancy should be offered intrapartum antibiotic prophylaxis (IAP) or testing in late pregnancy and antibiotics if still positive. IAP should also be offered to women with a previous baby with GBS disease, women in preterm labor, and women with a fever during labor. Benzylpenicillin is the preferred antibiotic for GBS prophylaxis.

The recommended first-line treatment for eclampsia is intravenous magnesium sulphate. In this case, the woman has been diagnosed with eclampsia due to her tonic-clonic seizure and her symptoms of pre-eclampsia for the past two days. The initial management should focus on preventing further seizures and providing neuroprotection to the fetus, followed by considering delivery. It is important to monitor both the mother and fetus for signs of hypermagnesaemia, such as hyperreflexia and respiratory depression, and to continuously monitor their cardiotocography. Emergency caesarean section is not the most appropriate initial management as the woman needs to be stabilized first, given her high risk of having further seizures. Intravenous anti-hypertensives should also be administered after magnesium sulphate to lower her blood pressure. Intravenous furosemide and monitoring cardiotocography are not recommended as furosemide does not lower blood pressure in eclampsia. Intramuscular steroids are not necessary in this case as the woman is 35 weeks pregnant, and fetal lungs should be fully developed by now. Steroids are also not the most important management at this stage, even if the woman was earlier in her pregnancy.

Understanding Eclampsia and its Treatment

Eclampsia is a condition that occurs when seizures develop in association with pre-eclampsia, a pregnancy-induced hypertension that is characterized by proteinuria and occurs after 20 weeks of gestation. To prevent seizures in patients with severe pre-eclampsia and treat seizures once they develop, magnesium sulphate is commonly used. However, it is important to note that this medication should only be given once a decision to deliver has been made. In cases of eclampsia, an IV bolus of 4g over 5-10 minutes should be given, followed by an infusion of 1g/hour. During treatment, it is crucial to monitor urine output, reflexes, respiratory rate, and oxygen saturations. Respiratory depression can occur, and calcium gluconate is the first-line treatment for magnesium sulphate-induced respiratory depression. Treatment should continue for 24 hours after the last seizure or delivery, as around 40% of seizures occur post-partum. Additionally, fluid restriction is necessary to avoid the potentially serious consequences of fluid overload.

In summary, understanding the development of eclampsia and its treatment is crucial in managing this potentially life-threatening condition. Magnesium sulphate is the primary medication used to prevent and treat seizures, but it should only be given once a decision to deliver has been made. Monitoring vital signs and urine output is essential during treatment, and calcium gluconate should be readily available in case of respiratory depression. Finally, fluid restriction is necessary to avoid complications associated with fluid overload.

Termination of Pregnancy in the UK

The UK’s current abortion law is based on the 1967 Abortion Act, which was amended in 1990 to reduce the upper limit for termination from 28 weeks to 24 weeks gestation. To perform an abortion, two registered medical practitioners must sign a legal document, except in emergencies where only one is needed. The procedure must be carried out by a registered medical practitioner in an NHS hospital or licensed premise.

The method used to terminate a pregnancy depends on the gestation period. For pregnancies less than nine weeks, mifepristone (an anti-progestogen) is administered, followed by prostaglandins 48 hours later to stimulate uterine contractions. For pregnancies less than 13 weeks, surgical dilation and suction of uterine contents is used. For pregnancies more than 15 weeks, surgical dilation and evacuation of uterine contents or late medical abortion (inducing ‘mini-labour’) is used.

The 1967 Abortion Act outlines the circumstances under which a person shall not be guilty of an offence under the law relating to abortion. These include if two registered medical practitioners are of the opinion, formed in good faith, that the pregnancy has not exceeded its 24th week and that the continuance of the pregnancy would involve risk, greater than if the pregnancy were terminated, of injury to the physical or mental health of the pregnant woman or any existing children of her family. The limits do not apply in cases where it is necessary to save the life of the woman, there is evidence of extreme fetal abnormality, or there is a risk of serious physical or mental injury to the woman.

The copper intrauterine device is the recommended form of contraception for individuals with breast cancer. Hormonal forms of contraception are not recommended and are rated as a Category 4 risk, which is deemed unacceptable for the patient’s health.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Antenatal care guidelines were issued by NICE in March 2008, which included specific points for the care of healthy pregnant women. Nausea and vomiting can be treated with natural remedies such as ginger and acupuncture on the ‘p6’ point, as recommended by NICE. Antihistamines, with promethazine as the first-line option according to the BNF, can also be used. Adequate vitamin D intake is crucial for the health of both the mother and baby, and women should be informed about this at their booking appointment. The Chief Medical Officer advises all pregnant and breastfeeding women to take a daily supplement containing 10 micrograms of vitamin D, with particular care taken for those at risk. In 2016, new guidelines were proposed by the Chief Medical Officer regarding alcohol consumption during pregnancy. The government now advises pregnant women not to drink any alcohol to minimize the risk of harm to the baby.

The recommended treatment for the patient’s likely diagnosis of trichomoniasis is oral metronidazole, either as a 7-day course of 200mg or a one-time dose of 2g. Intramuscular ceftriaxone, benzathine benzylpenicillin, and oral doxycycline are not indicated for the treatment of trichomoniasis. Oral azithromycin is also not effective for this condition.

Understanding Trichomonas vaginalis and its Comparison to Bacterial Vaginosis

Trichomonas vaginalis is a type of protozoan parasite that is highly motile and flagellated. It is known to cause trichomoniasis, which is a sexually transmitted infection. The infection is characterized by symptoms such as offensive, yellow/green, frothy vaginal discharge, vulvovaginitis, and strawberry cervix. The pH level is usually above 4.5, and in men, it may cause urethritis.

To diagnose trichomoniasis, a wet mount microscopy is conducted to observe the motile trophozoites. The treatment for trichomoniasis involves oral metronidazole for 5-7 days, although a one-off dose of 2g metronidazole may also be used.

When compared to bacterial vaginosis, trichomoniasis has distinct differences. Bacterial vaginosis is caused by an overgrowth of bacteria in the vagina, while trichomoniasis is caused by a protozoan parasite. The symptoms of bacterial vaginosis include a thin, grayish-white vaginal discharge with a fishy odor, and a pH level above 4.5. Unlike trichomoniasis, bacterial vaginosis is not considered a sexually transmitted infection.

In conclusion, understanding the differences between trichomoniasis and bacterial vaginosis is crucial in diagnosing and treating these conditions effectively. Proper diagnosis and treatment can help prevent complications and improve overall health and well-being.

To confirm or rule out ectopic pregnancy, the recommended investigation is transvaginal ultrasound. This is because it provides clearer images of the uterus, ovaries, and endometrium, making it more effective in detecting ectopic pregnancies compared to transabdominal scans. While serum Beta-HCG levels are helpful in managing ectopic pregnancies, a single test cannot completely rule out the possibility. Pregnant women are generally advised against undergoing CT scans and abdominal X-rays.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingotomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women with no other risk factors for infertility, while salpingotomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingotomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Bacterial vaginosis is a condition characterized by the excessive growth of mainly bacteria.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

Clomifene is the recommended first-line treatment for infertility in patients with PCOS. This patient has been diagnosed with PCOS, which can cause infertility and other symptoms such as hirsutism. Clomifene works by inducing ovulation and has been shown to improve fertility outcomes in these patients.

Goserelin is not a suitable treatment for infertility in PCOS patients. It is a gonadotrophin-releasing hormone agonist used for conditions such as prostate carcinoma, endometriosis, and dysfunctional uterine bleeding. In-vitro fertilisation is not typically the first option for improving fertility in PCOS patients and is usually considered later on.

While metformin is an important drug in the management of PCOS, it is not the primary treatment for improving fertility. It is often prescribed in combination with clomifene to address metabolic issues associated with PCOS. However, clomifene is the key drug for improving overall fertility outcomes in these patients.

Managing Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is associated with high levels of luteinizing hormone and hyperinsulinemia. Management of PCOS is complex and varies depending on the individual’s symptoms. Weight reduction is often recommended, and a combined oral contraceptive pill may be used to regulate menstrual cycles and manage hirsutism and acne. If these symptoms do not respond to the pill, topical eflornithine or medications like spironolactone, flutamide, and finasteride may be used under specialist supervision.

Infertility is another common issue associated with PCOS. Weight reduction is recommended, and the management of infertility should be supervised by a specialist. There is ongoing debate about the most effective treatment for infertility in patients with PCOS. Clomifene is often used, but there is a potential risk of multiple pregnancies with anti-oestrogen therapies like clomifene. Metformin is also used, either alone or in combination with clomifene, particularly in patients who are obese. Gonadotrophins may also be used to stimulate ovulation. The Royal College of Obstetricians and Gynaecologists (RCOG) published an opinion paper in 2008 and concluded that on current evidence, metformin is not a first-line treatment of choice in the management of PCOS.

Understanding Puerperal Pyrexia

Puerperal pyrexia is a condition that occurs when a woman experiences a fever of more than 38ºC within the first 14 days after giving birth. The most common cause of this condition is endometritis, which is an infection of the lining of the uterus. Other causes include urinary tract infections, wound infections, mastitis, and venous thromboembolism.

If a woman is suspected of having endometritis, it is important to seek medical attention immediately. Treatment typically involves intravenous antibiotics such as clindamycin and gentamicin until the patient is afebrile for more than 24 hours. It is important to note that puerperal pyrexia can be a serious condition and should not be ignored. By understanding the causes and seeking prompt medical attention, women can receive the necessary treatment to recover from this condition.

For symptomatic men with Chlamydia, it is recommended to notify all sexual partners from the 4 weeks prior to the onset of symptoms. As for women and asymptomatic men, all sexual partners from the last 6 months or the most recent partner should be notified. Pregnant women should undergo a test of cure (TOC) 6 weeks after infection, according to BASHH guidelines. Performing a TOC earlier than 6 weeks may result in a false positive due to the presence of nonviable Chlamydia DNA on the NAAT. However, uncomplicated Chlamydia infection in men and non-pregnant women does not require a routine TOC.

Chlamydia is a common sexually transmitted infection caused by Chlamydia trachomatis. It is prevalent in the UK, with approximately 1 in 10 young women affected. The incubation period is around 7-21 days, but many cases are asymptomatic. Symptoms in women include cervicitis, discharge, and bleeding, while men may experience urethral discharge and dysuria. Complications can include epididymitis, pelvic inflammatory disease, and infertility.

Traditional cell culture is no longer widely used for diagnosis, with nuclear acid amplification tests (NAATs) being the preferred method. Testing can be done using urine, vulvovaginal swab, or cervical swab. Screening is recommended for sexually active individuals aged 15-24 years, and opportunistic testing is common.

Doxycycline is the first-line treatment for Chlamydia, with azithromycin as an alternative if doxycycline is contraindicated or not tolerated. Pregnant women may be treated with azithromycin, erythromycin, or amoxicillin. Patients diagnosed with Chlamydia should be offered partner notification services, with all contacts since the onset of symptoms or within the last six months being notified and offered treatment.

Liver Disorders in Pregnancy: Differential Diagnosis

During pregnancy, various liver disorders can occur, each with its own set of symptoms and potential complications. Here are some of the most common liver disorders that can occur during pregnancy and their distinguishing features:

1. Hyperemesis gravidarum: This is the most severe form of nausea and vomiting in pregnancy, which can lead to weight loss, dehydration, and electrolyte imbalances. It is characterised by persistent nausea and vomiting, and may require hospitalisation.

2. Acute fatty liver of pregnancy: This is a rare but serious complication that can occur in the third trimester. It is characterised by microvesicular steatosis in the liver, which can lead to liver insufficiency. Symptoms include malaise, nausea and vomiting, right upper quadrant and epigastric pain, and acute renal failure.

3. Intrahepatic cholestasis of pregnancy: This is the most common pregnancy-related liver disorder, characterised by generalised itching, particularly in the palms and soles, and jaundice. It is caused by hormonal changes and can lead to fetal complications if not treated promptly.

4. Pre-eclampsia: This is a disorder of widespread vascular malfunction that occurs after 20 weeks of gestation. It is characterised by hypertension and proteinuria, with or without oedema.

5. Biliary tract disease: This is a broad spectrum of disorders ranging from asymptomatic gallstones to cholecystitis and choledocholithiasis. Symptoms include biliary colic, inflammation of the gall bladder wall, and obstruction of the common bile duct.

It is important to differentiate between these liver disorders in pregnancy, as each requires a different approach to management and treatment. Consultation with a healthcare provider is recommended for proper diagnosis and management.

Understanding Cervical Cancer and Abnormal Smear Test Results

Cervical cancer is a common malignancy in women worldwide and can be detected through routine cervical screening. An abnormal Papanicolaou (‘smear’) test result is the most common finding in patients with cervical cancer. Physical symptoms may include abnormal vaginal bleeding, vaginal discomfort, malodorous discharge, and dysuria. Referral for colposcopy and biopsy should be made within two weeks for patients with symptoms of cervical cancer. Women with a cervical cytology result of moderate, high-grade dyskaryosis, suspected invasive cancer or glandular neoplasia should also be referred for colposcopy within two weeks. Cervical cauterisation with silver nitrate is not associated with the development of cervical cancer and is used to treat cervical ectropion. Endocervical swab for Chlamydia spp. may be necessary for women presenting with mucopurulent cervicitis. Understanding these guidelines and symptoms can help with early detection and treatment of cervical cancer.

When it comes to methotrexate, it is important to discontinue the drug at least six months before attempting to conceive, regardless of gender. This is because methotrexate can potentially harm sperm in males and cause early abortion in females. By allowing for a full wash-out period, the risk of DNA changes in both gametes can be minimized. While some studies suggest that paternal exposure to methotrexate within 90 days before pregnancy may not lead to congenital malformations, stillbirths, or preterm births, current guidelines recommend avoiding the drug for six months to ensure proper folic acid repletion. Therefore, options suggesting stopping methotrexate for only one or three months before conception are incorrect.

Managing Rheumatoid Arthritis During Pregnancy

Rheumatoid arthritis (RA) is a condition that commonly affects women of reproductive age, making issues surrounding conception and pregnancy a concern. While there are no official guidelines for managing RA during pregnancy, expert reviews suggest that patients with early or poorly controlled RA should wait until their disease is more stable before attempting to conceive.

During pregnancy, RA symptoms tend to improve for most patients, but only a small minority experience complete resolution. After delivery, patients often experience a flare-up of symptoms. It’s important to note that certain medications used to treat RA are not safe during pregnancy, such as methotrexate and leflunomide. However, sulfasalazine and hydroxychloroquine are considered safe.

Interestingly, studies have shown that the use of TNF-α blockers during pregnancy does not significantly increase adverse outcomes. However, many patients in these studies stopped taking the medication once they found out they were pregnant. Low-dose corticosteroids may also be used to control symptoms during pregnancy.

NSAIDs can be used until 32 weeks, but should be withdrawn after that due to the risk of early closure of the ductus arteriosus. Patients with RA should also be referred to an obstetric anaesthetist due to the risk of atlanto-axial subluxation. Overall, managing RA during pregnancy requires careful consideration and consultation with healthcare professionals.

Breast cancer is the second most common cancer in women and the leading cause of cancer death among women worldwide. Tamoxifen is a drug that can be used to treat breast cancer that requires estrogen to grow. It works by either blocking estrogen receptors or blocking the production of estrogen. For women with estrogen receptor-positive breast cancer, continuing tamoxifen for 10 years instead of stopping at 5 years can further reduce the risk of recurrence and mortality. However, tamoxifen does not affect the risk of breast cancer recurrence. The risk of endometrial cancer is slightly increased with tamoxifen treatment. Screening modalities include breast self-examination, clinical breast examination, mammography, ultrasonography, and magnetic resonance imaging. Early detection is crucial in preventing breast cancer, and screening intervals may need to be shortened to prevent more deaths. Physical examination and biopsy are also important diagnostic approaches. Treatment for breast cancer typically involves surgery, radiation therapy, and adjuvant hormone or chemotherapy when necessary.

If a woman experiences secondary amenorrhoea and has low levels of gonadotrophins, it suggests that the cause is related to the hypothalamus. High levels of gonadotrophins would indicate premature ovarian failure, while high levels of LH and androgens would suggest polycystic ovarian syndrome. Normal levels of prolactin and thyroxine have been observed in this woman.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

A woman with a moderate or high risk of pre-eclampsia, such as this patient who has a family history of pre-eclampsia and type 1 diabetes mellitus, should take aspirin 75-150mg daily from 12 weeks gestation until delivery to reduce the risk of developing pre-eclampsia.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.